Jump Financial LLC Sells 8,567 Shares of Natera, Inc. (NASDAQ:NTRA)

Jump Financial LLC cut its stake in Natera, Inc. (NASDAQ:NTRA) by 11.9% in the fourth quarter, Holdings Channel.com reports. The firm owned 63,317 shares of the medical research company’s stock after selling 8,567 shares during the period. Jump Financial LLC’s holdings in Natera were worth $10,023,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. XTX Topco Ltd bought a new stake in shares of Natera during the fourth quarter valued at approximately $548,000. Mariner LLC boosted its stake in Natera by 7.0% during the fourth quarter. Mariner LLC now owns 9,769 shares of the medical research company’s stock worth $1,546,000 after buying an additional 636 shares in the last quarter. Townsquare Capital LLC bought a new stake in Natera in the 4th quarter valued at $248,000. Sterling Capital Management LLC raised its stake in shares of Natera by 608.6% in the 4th quarter. Sterling Capital Management LLC now owns 14,647 shares of the medical research company’s stock valued at $2,319,000 after buying an additional 12,580 shares in the last quarter. Finally, Harbert Fund Advisors Inc. bought a new position in shares of Natera during the 4th quarter worth about $712,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

NTRA has been the subject of several recent research reports. Canaccord Genuity Group reissued a “buy” rating and issued a $180.00 price target on shares of Natera in a research report on Wednesday, February 26th. Robert W. Baird increased their target price on Natera from $183.00 to $188.00 and gave the stock an “outperform” rating in a report on Friday, February 28th. BTIG Research reaffirmed a “buy” rating on shares of Natera in a research note on Friday, February 28th. The Goldman Sachs Group upped their price target on Natera from $160.00 to $190.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th. Finally, Guggenheim lifted their price objective on Natera from $170.00 to $200.00 and gave the company a “buy” rating in a report on Friday, January 17th. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, Natera presently has a consensus rating of “Moderate Buy” and a consensus target price of $175.76.

Natera Stock Up 2.2 %

Shares of NTRA opened at $151.74 on Wednesday. The business’s fifty day moving average price is $151.62 and its two-hundred day moving average price is $152.40. The firm has a market capitalization of $20.51 billion, a price-to-earnings ratio of -86.22 and a beta of 1.80. Natera, Inc. has a 52 week low of $83.13 and a 52 week high of $183.00. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.01. The business had revenue of $476.10 million for the quarter, compared to analysts’ expectations of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. On average, analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

Insider Transactions at Natera

In other news, Director Gail Boxer Marcus sold 4,000 shares of the firm’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $147.69, for a total value of $590,760.00. Following the transaction, the director now directly owns 9,704 shares in the company, valued at $1,433,183.76. This trade represents a 29.19 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Steven Leonard Chapman sold 78,553 shares of the company’s stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total value of $12,958,888.41. Following the completion of the sale, the chief executive officer now owns 267,629 shares of the company’s stock, valued at $44,150,756.13. This represents a 22.69 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 325,922 shares of company stock worth $51,603,664 in the last quarter. 7.60% of the stock is owned by company insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.